Michael Barbella, Managing Editor02.22.24
Bright Uro is $23 million richer these days, having closed a Series A financing round led by Laborie Medical Technologies.
The funding money will be used to achieve U.S. Food and Drug Administration 510(k) clearance of the Glean Urodynamics System (Glean) and launch the product in the United States this year. Glean is a comprehensive system that enables wireless, catheter-free urodynamics and aims to revolutionize the testing process by giving clinicians more accurate data with actionable insight to aid in clinical decision-making.
“Laborie looks forward to leveraging our expertise and leadership in the global urology market to support the Bright Uro team,” Laborie President/CEO Michael Frazzette said. “The Glean system is a very novel technology. This investment furthers our commitment to preserve and restore human dignity while improving patient access and outcomes.”
In addition to announcing the funding round, Bright Uro also appointed two industry veterans to its executive team: Suranjan Roychowdhury, Ph.D. as chief Product Development officer and Casey Kanel as chief commercial officer. Roychowdhury is a seasoned professional with extensive experience leading R&D and clinical at both startups and large medical device companies, including AMS, Cogentix, and Boston Scientific Corp. Kanel brings a track record of commercial success with more than 30 years of experience in urology and urogynecology device sales. After spending the majority of his career with Medtronic, Kanel led the U.S. launch of Bulkamid for Contura until its successful acquisition by Axonics in 2020.
“I am so proud of our team for achieving this incredible milestone! In just 15 months since securing an exclusive IP license from the Cleveland Clinic, we have built, tested, and manufactured not one device, but a highly complex system, including single-use disposable sensors, male and female insertion tools, a reusable uroflowmeter, and multiple software apps," Bright Uro Founder/CEO Derek Herrera stated. "At Bright Uro, our people are our most important asset. Casey and Suranjan are the right leaders joining at the perfect time to have an exponential impact as we continue on the path to bring Glean to market.”
Based in Irvine, Calif., Bright Uro’s mission is to transform care of lower urinary tract symptoms (LUTS) with its technology that could disrupt outdated urodynamics approaches. The company’s investigational Glean Urodynamics System is designed to enable wireless, catheter-free urodynamics monitoring.
Headquartered in Portsmouth, N.H., Laborie is a global medical technology company focused on urology, urogynecology, gastroenterology, obstetrics, gynecology, and neonatal health. The company manufactures and deliver high-impact diagnostic and therapeutic products that help clinicians and hospitals preserve and restore patient dignity. Laborie is a portfolio company of Patricia Industries.
The funding money will be used to achieve U.S. Food and Drug Administration 510(k) clearance of the Glean Urodynamics System (Glean) and launch the product in the United States this year. Glean is a comprehensive system that enables wireless, catheter-free urodynamics and aims to revolutionize the testing process by giving clinicians more accurate data with actionable insight to aid in clinical decision-making.
“Laborie looks forward to leveraging our expertise and leadership in the global urology market to support the Bright Uro team,” Laborie President/CEO Michael Frazzette said. “The Glean system is a very novel technology. This investment furthers our commitment to preserve and restore human dignity while improving patient access and outcomes.”
In addition to announcing the funding round, Bright Uro also appointed two industry veterans to its executive team: Suranjan Roychowdhury, Ph.D. as chief Product Development officer and Casey Kanel as chief commercial officer. Roychowdhury is a seasoned professional with extensive experience leading R&D and clinical at both startups and large medical device companies, including AMS, Cogentix, and Boston Scientific Corp. Kanel brings a track record of commercial success with more than 30 years of experience in urology and urogynecology device sales. After spending the majority of his career with Medtronic, Kanel led the U.S. launch of Bulkamid for Contura until its successful acquisition by Axonics in 2020.
“I am so proud of our team for achieving this incredible milestone! In just 15 months since securing an exclusive IP license from the Cleveland Clinic, we have built, tested, and manufactured not one device, but a highly complex system, including single-use disposable sensors, male and female insertion tools, a reusable uroflowmeter, and multiple software apps," Bright Uro Founder/CEO Derek Herrera stated. "At Bright Uro, our people are our most important asset. Casey and Suranjan are the right leaders joining at the perfect time to have an exponential impact as we continue on the path to bring Glean to market.”
Based in Irvine, Calif., Bright Uro’s mission is to transform care of lower urinary tract symptoms (LUTS) with its technology that could disrupt outdated urodynamics approaches. The company’s investigational Glean Urodynamics System is designed to enable wireless, catheter-free urodynamics monitoring.
Headquartered in Portsmouth, N.H., Laborie is a global medical technology company focused on urology, urogynecology, gastroenterology, obstetrics, gynecology, and neonatal health. The company manufactures and deliver high-impact diagnostic and therapeutic products that help clinicians and hospitals preserve and restore patient dignity. Laborie is a portfolio company of Patricia Industries.